Neisserial antigens

Details Neisserial antigens Neisserial antigens

2004-06-08

2010-02-02

Mondesi, Robert B (Department: 1645)

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

Bacterium or component thereof or substance produced by said...

C424S249100, C424S234100, C424S190100, C435S069100, C435S069700, C435S252300, C530S350000, C536S023100, C536S023700

Reexamination Certificate

active

07655245

ABSTRACT:
The invention provides proteins fromNeisseria meningitidis(strains A & B) and fromNeisseria gonorrhoeae, including amino acid sequences, the corresponding nucleotide sequences, expression data, and serological data. The proteins are useful antigens for vaccines, immunogenic compositions, and/or diagnostics.

REFERENCES:
patent: 5288641 (1994-02-01), Roizman
patent: 5422120 (1995-06-01), Kim
patent: 5580859 (1996-12-01), Felgner et al.
patent: 5591624 (1997-01-01), Barber et al.
patent: 5763188 (1998-06-01), Ohno et al.
patent: 5785974 (1998-07-01), Casal Alvarez et al.
patent: 6100380 (2000-08-01), Green et al.
patent: 6127180 (2000-10-01), Narva et al.
patent: 6150502 (2000-11-01), Strachan et al.
patent: 6583275 (2003-06-01), Doucette-Stamm et al.
patent: 6914131 (2005-07-01), Scarlato et al.
patent: 0 176 170 (1986-04-01), None
patent: 0 334 301 (1989-09-01), None
patent: 0 345 242 (1989-12-01), None
patent: 0 415 731 (1991-03-01), None
patent: 2 200 651 (1988-08-01), None
patent: WO 90/11092 (1990-10-01), None
patent: WO 92/05266 (1992-04-01), None
patent: WO 93/06223 (1993-04-01), None
patent: WO 93/07282 (1993-04-01), None
patent: WO 93/07283 (1993-04-01), None
patent: WO 93/14778 (1993-08-01), None
patent: WO-9318150 (1993-09-01), None
patent: WO 95/13796 (1995-05-01), None
patent: WO 95/30763 (1995-11-01), None
patent: WO-9605858 (1996-02-01), None
patent: WO-9612020 (1996-04-01), None
patent: WO 96/29412 (1996-09-01), None
patent: WO-9631618 (1996-10-01), None
patent: WO-9711181 (1997-03-01), None
patent: WO 98/20734 (1998-05-01), None
patent: WO-9924578 (1999-05-01), None
patent: WO-9955873 (1999-11-01), None
patent: WO-9957280 (1999-11-01), None
Gomez et al. Vaccine 14: 1340-1346, 1996.
Teerlink et al. J. Exp. Med. 166: 63-76, 1987 (Abstract Only).
Forest et al. Gene 192: 165-169, 1997.
Ala'Aldeen et al. Vaccine 12: 535-541, 1994(Abstract Only).
Houghten et al. (Vaccines, 1986, Edited by Fred Brown: Cold Spring Harbor Laboratory).
Lederman et al (Molecular Immunology 28:1171-1181, 1991).
Li et al (Proc. Natl. Acad. Sci. USA 77:3211-3214, 1980).
Page 46 of Cruse et al., Illustrated Dictionary of Immunology, 2nd Edn., CRC Press, 2003.
Poulsen et al, Infect. Immun. 57, 3097-3105, 1989.
Pohlner et al, Nature 325, 458-462, 1987 (Abstract Only).
Ala'Aldeen et al., The Meningococcal Transferrin-Binding Proteins 1 and 2 Are Both Surface Exposed and Generate Bactericidal Antibodies Capable of Killing Homologous and Heterologous Strains,Vaccine14(1): 49-53 (1996).
Altschul et al., Gapped Blast and PSI-Blast: A New Generation of Protein Database Search Programs,Nucl. Acids Res., 25: 2289-3402 (1997).
Berkner, Development of Adenovirus Vectors for the Expression of Heterologous Genes,Biotechniques6: 616-629 (1988).
Connelly et al., In Vivo Gene Delivery and Expression of Physiological Levels of Fuctional Human Factor VIII in Mice,Human Gene Therapy6: 185-193 (1995).
Costantino et al., Development and Phase I Clinical Testing of a Conjugate Vaccine Against Meningococcus A and C,Vaccine10: 691-698 (1992).
Donnelly et al., DNA Vaccines,Annu. Rev. Immunol. 15: 617-648 (1997).
Esposti e al., Critical Evaluation of the Hydropathy of Membrane Proteins,Eur. J. Biochem. 190:207-219 (1990).
Gao et al., Indentification and Characterization of T Helper Epitopes in the Nucleoprotein of Influenza A Virus,J. Immunol. 143: 3007-3014 (1989).
Jolly, Viral Vector Systems for Gene Therapy,Cancer Gene Therapy1:51-64 (1994).
Kimura et al., Retroviral Delivery of DNA Into the Livers of Transgenic Mice Bearing Premalignant and Malignant Hepatocellular Carcinomas,Human Gene Therapy5:845-852 (1994).
Kohler et al., Continuous Cultures of Fused Cells Secreting Antibody of Predefined Specificity,Nature256: 495-496, 1975.
Lieberman et al., Safety and Immunogenicity of a Serogroups A/CNeisseria meningitidisOligosaccharide-Protein Conjugate Vaccine in Young Children,JAMA275(19): 1499-1503.
Morbidity and Mortality weekly report, Control and Prevention of Meningococcal Disease: Recommendations of the Advisory Committee on Immunization PRA, May 27, 2005.
Poolman, J.T. Development of a Meningococcal Vaccine,Infect. Agents Dis., 4:13-28 (1992).
Quakyi et al., Development of a Malaria T-Cell Vaccine for Blood Stage Immunity,Scand. J. Immunol, Suppl. 11: 9-16 (1992).
Roberts et al., Prediction of HIV Peptide Epitopes by a Novel Algorithm,AIDS Res. Hum. Retrovir., 12: 593-610 (1996).
Robinson et al., DNA Vaccines,Seminars in Immunology, 9: 271-283 (1997).
Romero et al., Current Status of Meningococcal Group B Vaccine Candidates: Capsular or Noncapsular?,Clin. Microbiol. Rev. 7(4): 559-575 (1994).
Rosenfeld et al., Adenovirus-Mediated Transfer of a Recombinant αL-Antitrypsin Gene to the Lung Epithelium In Vivo,Science252: 431-434 (1991).
Schuchat et al., Bacterial Meningitis in the United States in 1995,N. Engl. J. Med. 337(14): 970-976 (1997).
Szoka et al., Procedure for Preparation of Liposomes With Large Internal Aqueous Space and High Capture by Reverse-Phase Evaporation,Proc. Natl. Acad. Sci. USA75: 4194-4198 (1978).
Wedege, et al., Human Anitbody Response to a Group B Serotype 2A Meningococcal Vaccine Determined by Immunoblotting,Infection&Immunity, 51(2): 571-578 (1986).
Zollinger, New and Improved Vaccines Against Meningococcal Disease,New Generation vaccines, 2nded., Levine, et al. (eds.) Marcel Dekker, New York, 1997, 469-488.
Accession No. A61824 from PCT Patent Publication No. WO 97/11181. Created Mar. 9, 1998. (2 pages).
GenBank Accession No. A61829, last updated Mar. 9, 1998, located at <http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nuccore&id=3715998>, last visited on Nov. 20, 2008, 2 pages.
GenBank Accession No. AJ001740, last updated May 21, 1998, located at <http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nuccore&id=3152399>, last visited on Nov. 20, 2008, 2 pages.
GenBank Accession No. HIU20229, last updated Feb. 9, 1995, located at <http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nuccore&id=644850>, last visited on Nov. 20, 2008, 5 pages.
UniProtKB/TrEMBL Accession No. Q9X7H1, last updated Feb. 10, 2009, located at <http://www.uniprot.org/uniprot/Q9X7H1.txt> visited on May 12, 2009. (2 pages).
European Examination Report dated Nov. 20, 2008 for EP application No. 98 946 675.0. 3 pages.
European Examination Report dated Jun. 23, 2005 for EP application No. 98 946 675.0. 3 pages.
European Search Opinion and Partial European Search Report mailed Feb. 27, 2007, for EP Application 06076711.8 filed May 19, 2000, 16 pages.
Opposition to European Patent No. 1194560 B1, granted on Jul. 4, 2007 in the name of Novartis Vaccines and Diagnostics S.r.l.. Opposition filed by GlaxoSmithKline Biologicals S.A. On Apr. 4, 2008.
International Search Report mailed Dec. 8, 1999, for International Application No. PCT/IB98/01665, filed Oct. 9, 1998.
Berzofsky, J. A. (1985). “Intrinsic and Extrinsic Factors in Protein Antigenic Structure,”Science229(4717):932-940.
Harlow et al. (1988).Antibodies, A Laboratory Manual. Cold Spring Harbor Laboratory, Chapter 5, p. 76.
Martin et al. (1997). “Highly ConservedNeisseria meningitidisSurface Protein Confers Protection against Experimental Infection,” J. Exp. Med. 185(7):1173-1183.
Morris et al. (1994). “Nucleotide Sequence Analysis and Potential Environmental Distribution of a Ferric Pseudobactin Receptor Gene ofPseudomonassp. Strain M114,” Molecular and General Genetics 242:9-16.
Nassif et al. (1997). “Type-4 pili and meningococcal adhesiveness,” Gene 192:149-153.
Paruchuri et al. (Jan. 1990). “Identification and Characterization of aNeisseria gonorrhoeaGene e Encoding a Glycolipid-binding Adhesion,”Proceedings of the National Academy of Sciences USA87:333-337.
Rokbi et al. (1997) “Evaluation of Recombinant Transferrin-Binding Protein B Variants fromNeisseria meningitidisfor Their Ability To Induce Cross-Reactive and Bactericidal Antibodies against a Genetically Diverse Collection of Serogroup B Strains,”Infection and Im

Affiliated with

Also associated with

Rating

Neisserial antigens does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Neisserial antigens, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Neisserial antigens will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4167180